Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR Abstract #131

Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Aim(s): Reported here are the final results from a Phase II, open-label, multicenter study of pasireotide in patients with metastatic NETs whose symptoms of carcinoid syndrome (diarrhea and flushing) were inadequately controlled by octreotide LAR.
Materials and methods: Patients had histopathologically confirmed metastatic NETs, elevated 5-HIAA and/or CgA levels, and at least one measurable lesion (excluding bone). Patients initially received pasireotide 300µg sc bid and escalated every three days to a maximum of 1200µg sc bid in patients with suboptimal response to lower doses. Complete symptom control: a mean of ≤3 bowel movements (BM)/day, with ≤3 BM on any day, with no flushing episodes, for 15 consecutive days on a fixed-dose of pasireotide. Partial symptom control: a mean of <4 BM/day with ≤6 BM on any day, and a mean of <2 flushing episodes/day, for 15 consecutive days on a fixed-dose of pasireotide.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols

To read results and conclusion, please login ...

Further abstracts you may be interested in

#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Matthew Kulke
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#1296 The Application of Octreotide in a SINET Patient with Carcinoid Syndrome, Carcinoid Heart Disease and Carcinoid Crisis: A Case Report
Introduction: In Chinese population, small intestinal neuroendocrine tumor (SINET) only accounts for 2.2% of gastroenteropancreatic NET, while carcinoid syndrome, carcinoid heart disease (CHD) and carcinoid crisis are rarer.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Luohai Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#1684 An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: George Camba
Keywords: SSA, carcinoid, symptoms